

08th August, 2022

The BSE Limited 1st floor, New Trading Ring Rotunda Bldg, P.J Towers Dalal Street, Mumbai -400 001	The National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, G. Block Bandra Kurla Complex Bandra (East), Mumbai – 400 051
Script Code: 500259	Script Code: LYKALABS

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 the Board of Directors at its Meeting held today considered and approved;

1. Un-audited Standalone and Consolidated Financial Results for the First Quarter ended 30th June, 2022 together with Limited Review Report (enclosed).

Board noted the performance of the Company during the First Quarter ended 30th June, 2022 as under;

Standalone Financial Result Summary;

(Rs. in Lakhs)

Particulars	Quarter ended 30 th June, 2022	Quarter ended 31 st March, 2022	Quarter ended 30 th June, 2021
Revenue from Operation	2187.84	2768.30	4346.59
EBIDTA	660.39	1222.19	3033.69
Profit After Tax	29.65	-1494.39	1955.77

Consolidated Financial Result Summary;

(Rs. in Lakhs)

Particulars	Quarter ended 30 th	Quarter ended 31 st	Quarter ended 30 th
-------------	--------------------------------	--------------------------------	--------------------------------

	June, 2022	March, 2022	June, 2021
Revenue from Operation	2749.20	3518.51	4943.67
EBIDTA	701.98	1313.54	3036.80
Profit After Tax	56.35	-1476.52	1946.25

2. The Board has considered Scheme of Merger of Lyka Exports Limited (Subsidiary Company) with Lyka labs Limited (Holding Company) w.e.f. 01st April, 2022 (Appointed Date). As per the Valuation Report provided by Bhavesh M Rathod, Registered Valuer, the Exchange Ratio of shares between Lyka Labs Limited and Lyka Exports Limited is 23 shares of Lyka Labs Limited will be offered to shareholders of Lyka Exports Limited against every 100 shares held by them. Subject to approval by requisite Authorities
3. The Board has considered the Resignation Letter of Smt. Nehal N. Gandhi as a Director of the Company w.e.f. 08th August. 2022.
4. The Board has considered Appointment of Mr. Prashant P. Godha, as an Additional Director (Non-Executive) of the Company.
5. The Board has considered Appointment of Mr. Shashil P. Mendonsa, as an Additional Director (Non-Executive) of the Company.
6. The Board has considered Appointment of Mr. Babulal H. Jain, as an Additional Director (Independent) of the Company for a Term of 5 years w.e.f. 08th August, 2022.
7. The Board has approved Postal Ballot Notice for seeking the approval of the shareholders for Appointment of above Directors.
8. Mr. Kunal N. Gandhi continues as Managing Director and CEO of the Company and Mr. Babulal Jain is new chairman to preside over the Board Meetings and Shareholders Meetings.
9. The Board has considered reconstitution of various committees namely: Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee and Corporate Social Responsibility Committee. List of Members on the various committees attached.
10. The Board had adopted Corporate Social Responsibility Policy.

Meeting was commenced at 3.00 P.M.

Meeting was concluded at 05.15 P.M.

This is for your information and records.

Thanking You,
Yours faithfully,

For Lyka Labs Limited




Piyush G. Hindia
Company Secretary & Compliance Officer
ACS-5861

Encl.a/a

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2022


Particulars	(₹ in lakh)			
	Quarter Ended			Year Ended
	30th June, 2022 (Unaudited)	31st March, 2022 (Audited)	30th June, 2021 (Unaudited)	31st March, 2022 (Audited)
I. Revenue				
Revenue from Operations	2,187.84	2,768.30	4,346.59	16,434.88
Other income	68.39	66.00	53.11	271.98
II. Total Income	2,256.23	2,834.30	4,399.70	16,706.86
III. Expenses				
(a) Cost of Materials Consumed	683.84	628.04	672.47	2,693.80
(b) Purchase of Stock in trade	194.06	106.37	3.67	432.83
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(65.06)	(8.56)	(100.94)	(40.43)
(d) Employee benefits expense	370.84	424.78	399.37	1,621.96
(e) Finance Costs	280.06	290.95	688.97	1,992.13
(f) Depreciation and amortisation expense	341.36	913.13	205.15	1,538.87
(g) Other expenses	412.16	461.48	391.44	1,976.81
Total Expenses	2,217.26	2,816.19	2,260.13	10,215.97
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	38.97	18.11	2,139.57	6,490.89
V. Exceptional Items (Net)	0.08	280.31	-	466.83
VI. Profit / (Loss) before Tax	38.89	(262.20)	2,139.57	6,024.06
VII. Deferred Tax	6.06	1,261.34	174.98	2,033.83
VIII. Net Profit / (Loss) after Tax	32.83	(1,523.54)	1,964.59	3,990.23
IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(3.18)	29.15	(8.82)	12.69
X. Total Comprehensive Income / (Loss)	29.65	(1,494.39)	1,955.77	4,002.92
Paid up Equity Share Capital (Face value ₹ 10/- each)	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity				1,574.85
XI. Basic and diluted earnings per share	0.11	(5.32)	6.84	13.87




Notes:

1. The above unaudited standalone financial results were considered by the Audit Committee at their meeting held today which was approved and taken on record at the meeting of the Board of Directors held on 08th August, 2022.
2. During the quarter, the Company has capitalized Rs. 59.02 lakhs as “Self – Generated Intangible Assets” upon successful development of respective products.
3. The Company operates in one reportable business segment i.e. “Pharmaceuticals”.
4. The figures for previous year have been regrouped / rearranged wherever considered necessary.
5. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited standalone financials results for the quarter ended 30th June, 2022.
6. The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors, and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company’s financial results for the quarter ended 30th June, 2022.

Mumbai
08th August, 2022



For LYKA LABS LIMITED


Kunal N. Gandhi (DIN 01516156)
(Managing Director)



D. KOTHARY & CO.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Mehul N. Patel
Partner
Membership No. 132650


UDIN: 22132650A00ER

Place: Mumbai
Date: 8th August, 2022



Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2022

Particulars	Quarter Ended			Year Ended
	30th June, 2022	31st March, 2022	30th June, 2021	31st March, 2022
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
(₹ in lakh)				
I. Revenue				
Revenue from Operations	2,749.20	3,518.51	4,943.67	19,408.49
Other Income	71.78	53.31	47.01	209.42
II. Total Income	2,820.98	3,571.82	4,990.68	19,617.91
III. Expenses				
(a) Cost of Materials Consumed	683.84	628.04	672.47	2,693.80
(b) Purchase of Stock in trade	644.78	643.31	539.31	2,644.56
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(65.25)	(7.96)	(127.01)	(41.04)
(d) Employee benefits expense	401.24	462.99	446.78	1,805.76
(e) Finance Costs	290.71	298.98	692.62	2,012.88
(f) Depreciation and amortisation expense	358.62	945.81	213.09	1,734.94
(g) Other expenses	454.39	531.90	422.33	2,190.43
Total Expenses	2,768.33	3,503.07	2,859.59	13,041.33
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	52.65	68.75	2,131.09	6,576.58
V. Exceptional Items (Net)	(23.43)	280.31	-	651.88
VI. Profit / (Loss) before Tax	76.08	(211.56)	2,131.09	5,924.70
VII. Non Controlling Interest	11.20	7.91	(6.89)	(55.65)
VIII. Profit / (Loss) before Tax	64.88	(219.47)	2,137.98	5,980.35
IX. Deferred Tax	5.35	1,265.08	182.91	2,057.94
Tax relating to earlier years	-	22.43	-	22.43
X. Net Profit / (Loss) after Tax	59.53	(1,506.99)	1,955.07	3,899.97
XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(3.18)	30.47	(8.82)	14.01
XII. Total Comprehensive Income / (Loss)	56.35	(1,476.52)	1,946.25	3,913.98
XIII. Paid up Equity Share Capital (Face value Rs.10/- each)	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity				(1,535.15)
XIV. Basic and diluted earnings per share	0.20	(5.26)	6.80	13.57




Notes:

1. The above unaudited consolidated financial results were considered by the Audit Committee at their meeting held today which has been approved and taken on record at the meeting of the Board of Directors held 08th August, 2022.
2. During the quarter, the Holding Company has capitalized Rs.59.02 lakhs as "Self – Generated Intangible Assets" upon successful development of respective products.
3. The Group operates in one reportable business segment i.e. "Pharmaceuticals".
4. The figures for previous year have been regrouped / rearranged wherever considered necessary.
5. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited consolidated financials results for the quarter ended 30th June, 2022.
6. The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors, and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter ended 30th June, 2022.

For LYKA LABS LIMITED



Mumbai
08th August, 2022


Kunal N. Gandhi (DIN 01516156)
(Managing Director)



D. KOTHARY & CO.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Lyka Labs Limited** (the "Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:

Subsidiaries

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of 2 subsidiaries, whose interim financial results/information reflects total revenues of Rs. 668.50 lakhs, total net Profit/ (Loss) after tax of Rs. 37.89 lakhs for the quarter ended June 30, 2022, which have been reviewed by us.






D. KOTHARY & CO.

Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W


Mehul N. Patel
Partner
Membership No: 132650



UDIN: 22132650A00EYX8685

Place: Mumbai
Date: 8th August, 2022